Výsledky vyhledávání - "Aristides Maniatis"

Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)

Autor: Meryl Brod, Michael Højby Rasmussen, Suzanne Alolga, Jane F. Beck, Donald M. Bushnell, Kai Wai Lee, Aristides Maniatis

Publikováno v: PharmacoEconomics - Open. 7:121-138

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::99217914e161218c1d0a3694696ab562
https://doi.org/10.1007/s41669-022-00373-z

Zobrazit plný text záznamu

Response to Letter to the Editor From Chatelain et al: 'Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial'

Autor: Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa

Publikováno v: The Journal of Clinical Endocrinology & Metabolism.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::482d3699b162aefaf4c47390e16cee4a
https://doi.org/10.1210/clinem/dgad095

Zobrazit plný text záznamu

Psychometric Validation of the Growth Hormone Deficiency-Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency-Parent Treatment Burden Measure (GHD-PTB)

Autor: Meryl, Brod, Michael Højby, Rasmussen, Suzanne, Alolga, Jane F, Beck, Donald M, Bushnell, Kai Wai, Lee, Aristides, Maniatis

Publikováno v: PharmacoEconomics - open.

The aim was to evaluate the measurement properties of the Growth Hormone Deficiency-Child Treatment Burden Measure-Child (GHD-CTB-Child), a patient-reported outcome (PRO) for children aged 9 to13 years; the Growth Hormone Deficiency-Child Treatment B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bbb0209cc5035a20004c104779a9ce90
https://pubmed.ncbi.nlm.nih.gov/36255609

Zobrazit plný text záznamu

Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)

Autor: Donald M. Bushnell, Knud Vad, Michael Højby Rasmussen, Meryl Brod, Jacques Bedoin, Suzanne Alolga, Aristides Maniatis

Publikováno v: PharmacoEconomics Open

Objective The aim of this study was to perform psychometric testing of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM): a patient-reported outcome (PRO) for children with GHD aged 9 to 0.70), as was test–retest reliability for the SWB,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ce964400e60d12741a6bff03cf3979c
https://doi.org/10.1007/s41669-020-00252-5

Zobrazit plný text záznamu

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

Autor: Bradley S Miller, Joanne C Blair, Michael Højby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Böttcher, Stefano Stagi, Reiko Horikawa

Publikováno v: The Journal of clinical endocrinology and metabolism. 107(12)

Context Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated in children with GH deficiency (GHD). Objective To demonstrate efficacy and safety of somapacitan vs daily GH. Methods REAL4 is a randomised, multinational, ope

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f62535a04077c6dbe6ad6e8c40ece869
https://pubmed.ncbi.nlm.nih.gov/36062966

Zobrazit plný text záznamu

Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product

Autor: Abdelkader Rahmaoui, Aristides Maniatis, Dalia Moawad, Valerie Quarmby, Linda Yau, Martin Vanderlaan, Craig Azzolino, Cynthia Woods, Robert C. Olney

Publikováno v: Clinical Pharmacology and Therapeutics

Manufacturing process changes may alter the characteristics of a protein therapeutic. In 2009, somatropin (version 1.0), a recombinant human growth hormone therapeutic, underwent a manufacturing update (version 1.1). The immunogenicity of somatropin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e642f8f057234b962a813ded8d1c192
http://europepmc.org/articles/PMC7158213

Zobrazit plný text záznamu

PMON336 Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES): A multi-country, non-interventional, prospective, cohort study of patients receiving human growth hormone treatments under routine clinical care

Autor: Mitchell E Geffner, Lourdes Ibanez, Aristides Maniatis, Daria L Torre, Carol Huang, Feyza Darendelieler, Mehul Dattani, Mohamad Maghnie, Moshe Phillip, Jovanna Dahlgren, Reiko Horikawa, Roy Gomez, Scott P Kelly, Michael P Wajnrajch

Publikováno v: Journal of the Endocrine Society. 6:A630-A630

Background Children with growth hormone deficiency (GHD) are treated with recombinant human growth hormone (rhGH), usually administered as a daily subcutaneous injection. Long-acting hGH (LAGH) treatments (approved and in development) have the potent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::254d1dc5e3fd4ab40549ce1319740317
https://doi.org/10.1210/jendso/bvac150.1306

Zobrazit plný text záznamu

Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus

Autor: Petter, Bjornstad, Michal, Schäfer, Uyen, Truong, Melanie, Cree-Green, Laura, Pyle, Amy, Baumgartner, Yesenia, Garcia Reyes, Aristides, Maniatis, Sunil, Nayak, R Paul, Wadwa, Lorna P, Browne, Jane E B, Reusch, Kristen J, Nadeau

Publikováno v: Circulation. 138(25)

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of mortality in type 1 diabetes (T1D) and relates strongly to insulin resistance (IR). Lean and obese T1D adolescents have marked IR. Metformin improves surrogate markers of IR in T1D, but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::59f9b6800f2dcfd34ce57fd61bd1e869
https://pubmed.ncbi.nlm.nih.gov/30566007

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání